January 25, 2023
Rewind Therapeutics Raises Additional Funding and Adds Sunstone Life Science Ventures A/S as New Investor
– Claus Andersson, PhD, joins Rewind´s Board of Directors Leuven, Belgium, January...
Read More
November 29, 2022
Rewind Therapeutics Appoints Dr. Stephen Burbidge to its Management Team
– Former GlaxoSmithKline and Proximagen executive adds to Rewind´s drug discovery and...
Read More
October 19, 2022
ECTRIMS 2022, October 26-28, Amsterdam, The Netherlands
38th Congress of the European Committee for Treatment and Research in Multiple...
Read More
October 18, 2022
Rewind Therapeutics Appoints Irene Knuesel, PhD, as Chief Scientific Officer
– Former Roche Head of Neuroimmunology strengthens Rewind´s neuroimmunology and neurodegeneration expertise...
Read More